Ghost World (688399): Ghost World Inquiry Report
High-quality company in the field of molecular diagnostics.The company was founded in 2010 and is mainly engaged in the research and development, production and sales of in vitro diagnostic reagents and instruments.The company focuses on the field of molecular diagnostics and realizes the integrated operation of “instrument + reagent + service”.The company’佛山桑拿网s main products are nucleic acid molecular diagnostic reagents, nucleic acid purification reagents, dry chemical diagnostic reagents and detection equipment, which are widely distributed in the areas of infectious disease prevention and control, clinical detection, large-scale population screening and eugenics management. The company’s main financial indicators and profit forecasts.The company achieved operating income in 20182.31 ppm, an increase of 23 in ten years.18%; net profit attributable to mother is 0.64 ppm, an increase of 49 in ten years.58%; The company’s gross profit margin in 2018 was 81.67%, with a net interest rate of 27.67%, ROE is 19.69%, asset-liability budget 18.07%, the overall operating conditions are good.2019H1 achieves operating income1.2.2 billion; net profit attributable to mother 0.3 billion.The 都市夜网 gross profit margin and net sales margin for H1 2019 are 82, respectively.01% and 24.61%, ROE is 8.49%, asset-liability accounting 15.18%.We predict that the company’s operating revenue for 2019-2021 will be 2 respectively.8.2 billion, 3.5 billion and 4.29 trillion; net profit attributable to mothers is 0.8 billion, 1.01 ppm and 1.2.5 billion. Company valuation and inquiry analysis.This report focuses on the evaluation and analysis of companies using different methodologies and systems, and at the same time the corresponding reasonable inquiry interval.We use the historical estimation reference method to predict that the company estimate is 35.700 million, using the PE method to predict the company’s valuation is 35.8 ppm, using the DCF method to estimate the company’s valuation at 40.USD 300 million. Considering the growth of the company’s total revenue and profit scale, it is still in a rapid growth period. We mainly use the DCF estimation method, supplemented by the historical forecast reference method and the PE estimation method. We estimate and calculate the company.The reference method has a weight of 20%, the PE evaluation method has a weight of 20%, and the DCF estimation method has a weight of 60%. Finally, the company’s internal estimate is about 38.500 million.We assume that the number of new shares issued by the company this time is 14.66 million shares, and the total share capital of the company after the issuance is 58.62 million shares; according to the company’s predicted market value, the corresponding replacement of the company is 65.65 yuan / share, the recommended inquiry range is[57.08, 74.21]yuan / share.(Note: This report is a reasonable reference and is not intended as a specific investment recommendation.) Risk warning: product development risk; industry policy risk; market competition risk.